The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Would appear to be the catalyst for this freefall. Well done lads for spanking your shareholders.
Exit of the NED is a little interesting??
Agreed it was an excellent piece. This is a share with some serious growth potential. Cyber security is only going one way !!
Excellent headline interview with CEO Kris Hagerman in this weekend's Sunday Telegraph business section.
There is a blog post on Sophos recent AGM by Roger Lawson which can be found here: hTTps://www.sharesoc.org/blog/regulations-and-law/sophos-interquest-government-policy/
Potentially misleading reference to Sophos and the NHS cyber attack in today's Telegraph by Frank Talbot of Citywire. He should have read this Telegraph article - hTtp://www.telegraph.co.uk/business/2017/05/17/sophos-outpaces-growth-targets-nhs-cyber-attack-boosts-prospects/ where he would have seen - "Mr Bray said the company does provide cyber security services to some NHS trusts and that they had been unaffected by the ransomware operation."
"Anyway , other than sophos does any bright young thing out there know of any smaller , similar companies to sophos that are worth a look ?" Londonmf, Re. your query a month ago. I much prefer GOS Systems to FLX. I explain why in post 5817 on the following TGL thread on ADVFN: "TGL - A Quantum Leap - $26 Billion Market - £2m Mk cap" Hedgehog 10011 Jun '15 - 21:26 - 5817 of 7549 https://uk.advfn.com/cmn/fbb/thread.php3?id=32338320&from=5817 GOS was previously owned by TGL, but was transferred to Intelicrypt Tactical Solutions after TGL delisted, with TGL shareholders receiving shares in ITS on a one-for-one basis. GOS is reported to be performing well, and ITS is expected to float within the medium term - perhaps even this year.
The SP here is showing bid 470.70 Is this correct? Lets hope so with more to follow.
Today's cyber attacks may well have boosted SOPH to its highest ever closing sp. Two large trades around that break out mid-afternoon and then a closing UT of just short of £2mn.
Good to see Numis Securities' new (June 1st) target is 544p
Even a 430p target is well underdone as SOPHS cruises past 450p. Could peter out soon with a pullback before resuming the trend.
Thanks for the good advice. FLX is also on my radar and the chart is looking bullish. The newsflow is positive, but they need to back that up with real performance to help their share price.
This is an industry I known nothing about . However , I was working in fund management during the dot com bubble and short lived gene therapy bubble so know full well that when a full on mania grabs the stock market valuations play no part in investment decisions. You just have to remember to leave the last ten percent on the table for someone else as when the tide turns you don't want to be left holding the baby. When I look at sophos I have no idea how high it might now go but not buying it because it looks expensive is completely missing the point. Anyway , other than sophos does any bright young thing out there know of any smaller , similar companies to sophos that are worth a look ? I see there is a company called Falanx which is tiny but has a very interesting looking chart . Thanks in advance for anyone who takes the time to reply.
There we go. 2 brokers increased their targets to 430p today.
Looks like every broker will have to re-run their forecasts as the market on SOPH has gone way ahead after their results. Only on Monday, I though they could reach 388p and they have blasted through that today. An absolute hold if ever I saw one.
yeehaw
A superb set of results.
After the gap up on 4th April. the price has remained strong with no pullback and is aiming for 388p. This agrees with Citi's view.
05-Apr-17 Citigroup Buy 325.00 380.00 Reiteration
Today Shore Capital issued a sell rating. Very questionable, seeing as the price gapped up and the increase is solid with limited profit taking. It also made a 52 week high and an all time high, which are bullish. Hold and next stop is 326p, but it will need a pullback to consolidate the move.
Good results today should send it well beyond it's all time high.
Its all time high is 293p. Today's acquisition, plus earnings report, should take the price beyond that. PS: And this is pure 100% speculation, Is this another UK tech company who's eventually going to be acquired by a large US tech firm like HP did with Autonomy.
PRO BREXIT Broker views on SOPH...... Sophos Group broker views Date Broker Recommendation Price Old target price New target price Notes 01 Jul 16 Morgan Stanley Overweight 206.20 350.00 350.00 Reiterates 30 Jun 16 JP Morgan Cazenove Overweight 206.20 - - Reiterates 30 Jun 16 Deutsche Bank Buy 206.20 272.00 272.00 Reiterates 30 Jun 16 Peel Hunt Buy 206.20 360.00 360.00 Reiterates
I thought they would very good company making actual profits its tricky now but looking more long term hopefully might drop little bit next week as think it will do very well.